文献速递胸部肿瘤放疗放疗物理与技术

L19-IL2 在肺癌小鼠模型中逆转放疗诱导的淋巴细胞减少

L19-IL2 reverts radiation-induced lymphopenia in a mouse model of lung cancer.
PubMed 文献 · Radiother Oncol · 2025-04-25

该研究建立小鼠2级放疗诱导淋巴细胞减少(RIL)模型,发现2级RIL未负面影响放疗后的无进展生存;放疗联合L19-IL2较单纯放疗诱导肿瘤生长延迟(p < 0.0005),并恢复和增加淋巴细胞与嗜酸性粒细胞计数(p < 0.05)。

要点

  • 大血管和椎骨照射诱导2级RIL,心脏照射仅诱导1级RIL。
  • 2级RIL未负面影响放疗后的无进展生存。
  • 放疗联合L19-IL2较单纯放疗诱导肿瘤生长延迟(p < 0.0005)。

核心结论

  • 利用所建立的小鼠RIL模型观察到RIL未负面影响放疗治疗结局。
  • L19-IL2可能是恢复淋巴细胞计数和逆转RIL的有前景策略。

研究设计与样本

  • C57BL6/J小鼠接受心脏、大血管或胸椎照射(10 Gy),每周监测绝对淋巴细胞计数(ALC)。
  • 荷瘤动物在RIL诱导前一天皮下注射Lewis肺癌细胞,肿瘤达212 ± 45 mm3时局部照射(10 Gy),并静脉注射L19-IL2(1 mg/kg,3次,隔日一次)或溶媒。
  • 肿瘤生长监测至超过治疗起始体积4倍,肿瘤细胞注射后2周进行流式细胞术免疫细胞分析。

主要发现

  • 在未荷瘤动物中,大血管和椎骨照射导致2级RIL,而心脏照射仅诱导1级RIL。
  • 在荷瘤动物中,大血管和椎骨照射后ALC分别下降16%和20%,确认RIL诱导。
  • 2级RIL未负面影响放疗后的无进展生存。
  • 放疗联合L19-IL2较单纯放疗诱导肿瘤生长延迟(p < 0.0005)。
  • L19-IL2给药后淋巴细胞和嗜酸性粒细胞计数恢复和增加(p < 0.05),大血管或椎骨照射未影响放疗-免疫治疗结局。

关键数值与推荐

  • 2级RIL定义为ALC下降≥20%。
  • L19-IL2剂量为1 mg/kg,静脉注射,3次,隔日一次。
  • 放疗联合L19-IL2较单纯放疗的肿瘤生长延迟p < 0.0005。
  • L19-IL2增加诱导性调节性T细胞和CD8+ T细胞,椎骨照射组p < 0.01,大血管照射组p = 0.07。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未述局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Over half of radiotherapy-treated cancer patients develop radiation-induced lymphopenia (RIL). Severe RIL has been associated with worse prognosis and survival, and recent studies suggested that RIL also affects immunotherapy efficacy. We aimed to develop murine grade 2 (≥20 % decrease in absolute lymphocyte counts (ALC)) RIL models and to examine the effects of RIL on progression-free survival upon radiotherapy-immunotherapy treatment. MATERIALS AND METHODS: C57BL6/J mice received heart, large blood vessels (LBV) or thoracic vertebrae irradiation (10 Gy) and ALC were monitored weekly. In tumour-bearing animals, Lewis Lung Carcinoma cells were injected subcutaneously one day prior to RIL induction. When tumours reached 212 ± 45 mm3, tumours were locally irradiated (10 Gy), and animals were injected with L19-IL2 (1 mg/kg, 3 times QOD) or vehicle intravenously. Tumour growth was monitored until reaching > 4 times treatment starting volume. Flow cytometry-based immune cell profiling was performed on blood collected 2 weeks post-tumour cell injection. RESULTS: Radiation treatment plans targeting lymphocyte-rich organs were optimized to achieve maximal target coverage while minimal dose to normal tissues. In naïve animals, LBV and vertebrae irradiation led to grade 2 RIL, however heart irradiation induced only grade 1 RIL. In tumour-bearing animals, RIL induction was confirmed by a 16 % and 20 % drop in ALC upon LBV and vertebrae irradiation, respectively. Grade 2 RIL did not negatively influence progression-free survival upon radiotherapy. Radiation combined with L19-IL2 induced a tumour growth delay compared to radiotherapy only (p < 0.0005). LBV or vertebrae irradiation did not affect radiotherapy-immunotherapy outcome, explained by the restored and increased lymphocyte and eosinophil counts upon L19-IL2 administration (p < 0.05). L19-IL2 increased inducible regulatory and CD8+ T cells, especially in vertebrae (p < 0.01) and LBV (p = 0.07) irradiated animals, respectively. CONCLUSION: Collectively, utilizing the developed murine RIL models, we observed that RIL did not negatively affect radiotherapy treatment outcome. L19-IL2 can be a promising strategy to restore lymphocyte counts and revert RIL.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Prades-Sagarra È, Lieuwes NG, Biemans R, et al. L19-IL2 reverts radiation-induced lymphopenia in a mouse model of lung cancer. Radiother Oncol. 2025. PMID: 40288691. doi:10.1016/j.radonc.2025.110908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。